Human immunodeficiency virus type 1 expressing the lamivudine- associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro

Journal of Infectious Diseases

Volumn 179, Issue 1, 1999, Pages 92-100

  Miller, Michael D ^a   Anton, Kristin E ^a   Mulato, Andrew S ^a   Lamy, Patrick D ^a   Cherrington, Julie M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIROGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENINE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0032937011     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314560     Document Type: Article

References (45)

1. Cherrington JM, Fuller MD, Mulato AS, et al. Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases. Antimicrob Agents Chemother 1996;40:1270-3.
2. Pauwels R, Balzarini J, Schols D, et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti-HIV agents. Antimicrob Agents Chemother 1988;32:1025-30.
3. Tsai CC, Follis KE, Sabo A, et al. Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis 1994;169:260-6.
4. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-7.
5. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8:261-72.
6. Yokota T, Konno K, Shigeta S, Holy A, Balzarini J, De Clercq E. Inhibitory effects of acyclic nucleoside phosphonate analogues in hepatitis B virus DNA synthesis in HB611 cells. Antiviral Chem Chemother 1994;5:57-63.
7. Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of aderovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997;176:1517-23.
8. Robbins BL, Greenhaw J, Connelly MC, Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonyl-methoxyethyl)-adenine in human lymphoid cells. Antimicrob Agents Chemother 1995;39:2304-8.
9. Balzarini J, Nave JF, Becker MA, Tatibana M, De Clercq E. Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver, and human erythrocytes. Nucleosides Nucleotides 1995;14:1861-71.
10. Perno CF, Balestra E, Aquaro S, et al. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl) adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Mol Pharmacol 1996;50:359-66.
11. Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach JL, Mitsuya H. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother 1995;39:2555-9.
12. Cherrington JM, Allen SJW, Bischofberger N, Chen MS. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β, and γ. Antiviral Chem Chemother 1995;6:217-21.
13. Mulato AS, Lamy PD, Miller MD, et al. Genotypic and phenotypic characterization of HIV-1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 1998;42:1620-8.
14. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
15. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Nad Acad Sci USA 1993;90:5653-6.
16. Boucher CAB, Keulen W, van Bommel T, et al. HIV-1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996;40:2404-9.
17. Cherrington JM, Mulato AS, Fuller MD, Chen MS. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl] adenine in vitro. Antimicrob Agents Chemother 1996;40:2212-6.
18. Fitzgibbon JE, Farnham AE, Sperber SJ, Kim H, Dubin DT. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol 1993;67:7271-5.
19. Demeter LM, Nawaz T, Morse G, et al. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis 1995;172:1480-5.
20. Lin PF, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of HIV-1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994;170:1157-64.
21. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997;41:757-62.
22. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the HIV-1 reverse transcriptase gene that encodes cross-resistance to ddI and ddC. J Virol 1992;66:7128-35.
23. Back NKT, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-9.
24. Richman DD. Drug resistance and its implications in the management of HIV infection. Antiviral Therapy 1997;2(suppl 4):41-58.
25. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129-42.
26. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
27. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-9.
28. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
29. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996;10:975-81.
30. St. Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
31. Larder BA. 3′-azido-3′k-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992;36:2664-9.
32. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
33. Cherrington JM, Mulato AS, Lamy PD, Margot NA, Anton KE, Miller MD. Adefovir dipivoxil (bis-POM-PM EA) therapy significantly decreases HIV RNA in patients with high-level zidovudine/lamivudine-resistant HIV [abstract 4]. In: 2nd International Workshop on Drug Resistance and Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998.
34. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997;41:1094-8.
35. Mellors JW, Hertogs K, Peeters F, et al. Susceptibility of clinical HIV-1 isolates to 1592US9 [abstract 687]. In: 5th Conference on Retroviruses and Opportunistic Infections (Chicago): program and abstracts. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
36. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997;71:1089-96.
37. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 19917;71:6662-70.
38. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
39. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis 1997;175:1502-6.
40. Goudsmit J, de Ronde A, de Rooij E, de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 1997;71:4479-84.
41. Zazzi M, Catucci M, De Milito A, et al. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment. Infection 1996;24:419-25.
42. Holodniy M, Katzenstein D, Mole L, Winters M, Merigan T. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. J Infect Dis 1996;174:854-7.
43. Miller V, Staszewski S. Prognostic value of phenotypic AZT-resistance for HIV progression [abstract 244]. In: Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany: European AIDS Clinical Society, 1997.
44. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant HIV-1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997;176:398-405.
45. Miller V, Phillips A. Dual resistance to zidovudine and lamivudine under zidovudine/lamivudine combination therapy: association with clinical progression [abstract 16]. In: Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication (St. Petersburg, FL). London: International Medical Press, 1997.